{"id":"nct:NCT06813911","kind":"trial","title":"Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD","authors":["Novartis Pharmaceuticals"],"author_count":1,"year":2025,"published":"2025-02-07","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT06813911","source_url":"https://clinicaltrials.gov/study/NCT06813911","archive_url":"https://space-kitty.com/papers/nct:NCT06813911","updated":"2026-10-14","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"The purpose of the study CTQJ230A12304, is to evaluate the efficacy, safety, and tolerability of pelacarsen (TQJ230) compared to placebo in participants with ASCVD who have elevated lipoprotein(a) (Lp(a)), and who are on background inclisiran treatment for elevated low-density lipoprotein cholesterol (LDL-C). Study has been terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Atherosclerotic Cardiovascular Disease (ASCVD)"],"details":{"acronym":"ADD-VANTAGE","status":"ACTIVE_NOT_RECRUITING","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":246,"sponsor":"Novartis Pharmaceuticals","conditions":["Atherosclerotic Cardiovascular Disease (ASCVD)"],"interventions":["DRUG: Pelacarsen","DRUG: Placebo","DRUG: Inclisiran"],"start_date":"2025-04-30","start_date_type":"ACTUAL","primary_completion_date":"2028-02-03","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"cardiovascular-innovation","name":"Cardiovascular Therapeutics","domain_slug":"medicine"}],"cited_in_dossiers":[]}